The Prevalence Of Small Airways Dysfunction In Asthma Patients And The Impact On The Asthma Control

Summary

Asthma, which are one of the most important causes of morbidity and mortality both in the world and in our country, constitute a very serious social and economic burden. An estimated 300 million people suffer from asthma worldwide, which is a major public health problem. Asthma is complex and heterogeneous chronic airway diseases that require a multifaceted approach. In asthma, small airways represent key regions of airflow obstruction. Although small airway dysfunction is known in chronic airway diseases, the importance of small airway dysfunction on disease control, exacerbations and quality of life, and the importance of taking place among treatable targets is not clear. Thus, there is an unmet need to assess its role in the control of the disease. Therefore, our primary aim in the study is to determine the frequency of small airway dysfunction measured by impulse oscillometry in Asthma patients. Our secondary aim is to evaluate the role of small airway dysfunction in disease severity, disease phenotypes, disease control, quality of life and its effect on predicting the risk of exacerbation and its role among treatable targets in Asthma.

Conditions

• Asthma
• Small Airway Disease

Interventions

DIAGNOSTIC_TEST

Impulse oscillometry

Impulse oscillometry test will be applied to all groups.

DIAGNOSTIC_TEST

Spirometric pulmonary function test

Spirometric pulmonary function test will be applied to all groups.

DIAGNOSTIC_TEST

Fractional exhaled nitric oxide (FENO) test

FeNO test will be applied to asthma group.

DIAGNOSTIC_TEST

Thorax Computed Tomography

Thorax Computed Tomography will be taken to the asthma group.

DIAGNOSTIC_TEST

Blood eosinophil level

The blood eosinophil level will be evaluated to determine the phenotype in the asthma group.

OTHER

Asthma control test

Asthma control test questions will be applied to the asthma group.

OTHER

Asthma quality of life scale

Asthma quality of life scale (AQLQ) will be applied to the asthma group.

DIAGNOSTIC_TEST

Chest X Ray

Chest X Ray will be applied to the healthy control group.

Sponsors & Collaborators

• Mersin University

  collaborator OTHER

• Sibel Naycı

  lead OTHER

Principal Investigators

• Sibel Nayci, Prof.Dr. · Mersin University, Department of Respiratory Diseases

• Demet Polat Yulug, Dr. · Mersin University, Department of Respiratory Diseases

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2019-10-01

Primary Completion

2020-09-01

Completion

2021-04-01

Countries

• Turkey (Türkiye)

Study Locations